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Abstract
Background: Chromosomal abnormalities have been associated with most human malignancies,
with gains and losses on some genomic regions associated with particular entities.
Methods: Of the 15429 cases collected for the Progenetix molecular-cytogenetic database, 5918
malignant epithelial neoplasias analyzed by chromosomal Comparative Genomic Hybridization
(CGH) were selected for further evaluation. For the 22 clinico-pathological entities with more than
50 cases, summary profiles for genomic imbalances were generated from case specific data and
analyzed.
Results: With large variation in overall genomic instability, recurring genomic gains and losses
were prominent. Most entities showed frequent gains involving 8q2, while gains on 20q, 1q, 3q, 5p,
7q and 17q were frequent in different entities. Loss "hot spots" included 3p, 4q, 13q, 17p and 18q
among others. Related average imbalance patterns were found for clinically distinct entities, e.g.
hepatocellular carcinomas (ca.) and ductal breast ca., as well as for histologically related entities
(squamous cell ca. of different sites).
Conclusion: Although considerable case-by-case variation of genomic profiles can be found by
CGH in epithelial malignancies, a limited set of variously combined chromosomal imbalances may
be typical for carcinogenesis. Focus on the respective regions should aid in target gene detection
and pathway deduction.
Background
The analysis of genomic abnormalities in malignant cell
clones has been performed for decades. Introduced in the
1960s, the evaluation of stained metaphase preparations
from tumor cells [1,2] has been widely employed in basic
research as well as in clinical practice. For analysis of com-
plex karyotypes, direct chromosomal inspection was
recently enhanced through multicolour in-situ hybridiza-
tion techniques: combinatorial multi-fluor FISH (M-FISH
[3]) and multicolour spectral karyotyping (SKY [4]).
In contrast to traditional or enhanced cytogenetic analy-
sis, molecular-cytogenetic methods rely on tumor DNA as
starting material for the exploration of genomic abnor-
malities. While fluorescent in-situ hybridization (FISH
[5,6]) allows for the detection of single or few numerical
and structural genomic features in non-dividing cells,
Comparative Genomic Hybridization (CGH [7,8]) per-
mits the screening of the whole tumor genome for
regional imbalances in the DNA content. Since CGH is
based on the hybridization of tumor and reference DNA
to standardized normal metaphase spreads, the spatial
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resolution of this technique is limited to several mega-
bases [9]. Also, the involvement of presumptive target
genes can only be inferred from the positional compari-
son of the genomic ratio profiles to the underlying chro-
mosomal matrix. However, recent molecular-cytogenetic
screening techniques (array-or matrix-CGH [10-12]) have
the potential for direct identification of oncogenetic target
genes.
Based on the comparably easy access to dividing tumor
cells, and the early reognition of specific cytogenetic aber-
rations in some entities [13-15], metaphase analysis has
been especially successfull in acute leukemias (review e.g.
in [16]) and other hematologic malignancies. This has
been reflected in the content of the Mitelman Database of
Chromosome Aberrations in Cancer [17], in which hema-
tologic neoplasias account for 73% of the database con-
tent (approx. 40,000 cases), while epithelial tumors
constitute only 12% (approx. 6,600 cases). In contrast,
especially through it's application to the genomic screen-
ing of frozen and archival tissue, the potential of CGH for
the analysis of solid tumors had been recognized early on
[7,18].
Some previous reviews of CGH data have either reported
on specific types of aberrations [19,20] or were focused on
solid tumors [21] or hematologic malignancies [22].
Struski  et al. [23] provided a census of 11,984 solid
tumors and hematologic malignancies analyzed by CGH.
Since in the majority of publications data is presented as
summary information (e.g. percentage of frequently
involved chromosomal regions), these data reviews were
able to develop a granular overview of the major regions
frequently imbalanced in different tumor entities.
Recently, Myllykangas et al. [24] provided an overview of
genomic gain/amplification patterns, thereby omitting
genomic losses. The study covered a large panel of human
neoplasias, based on more than 4500 single cases. The
authors were able to show a general relation genomic
amplification patterns to general histo-pathological fea-
tures, but could not prove overall relation of hot-spot sites
to some known genetic features.
The current study attempts a descriptive overview of
genomic imbalances in epithelial neoplasias, based on
published CGH data. Starting point for the data explora-
tion is the Progenetix molecular-cytogenetic database [25-
27], which was initiated in December 2000 to collect all
published cancer related CGH data and make it available
for reference and research purposes. In contrast to other
CGH data assembly attempts, but comparable to the
Mitelman Database of Chromosome Aberrations in Can-
cer, complete experimental results are collected on a case-
by-case basis. Publications describing (molecular-)
cytogenetic analyses of tumor samples and established
cell lines are mined for case specific annotation of the
experimental results. Focus is the exhaustive collection of
chromosomal CGH data, with occasional inclusion of
results from Metaphase banding, SKY and M-FISH data, as
well as the recent addition of array or matrix CGH [10,28]
results.
The detailed discussion of identified or suspected target
genes in the different chromosomal regions is not part of
this study. However, some examples of genes with onco-
gene and tumor suppressor function, respectively, will be
mentioned.
Methods
As of 2006-12-04, 15429 cases from 609 publications had
been included into the Progenetix database. Of those,
13818 had been analyzed by chromosomal CGH, either
alone or in combination with Metaphase analyses tech-
niques (355 cases). Minimum requirement for addition to
the database was the availability of case specific data for
the complete (molecular-) cytogenetic analysis result and
clinical diagnosis. In most cases, locus information was
available or could be inferred. Additional data (grading,
staging/TNM, age, gender, follow-up parameters) was
recorded if accessible. As main disease descriptors, diag-
nosis and locus information was recoded to ICD-O-3
standard [29], based on the available information.
For the purpose of this article, cases ascribed to epithelial
origin (ICD-O 8010/x-8780/x) were selected for further
analysis. This base dataset comprised 6899 cases, col-
lected from 254 publications. The oldest included data
was from 1994 [30], the latest from 2006 [31]. The largest
number of cases was found in a report about skin neopla-
sias (169 cases; [32]), followed by an extensive compari-
son of BRCA1 and BRCA2 mutated breast carcinomas
(132 cases; [33]). Only 8 articles were single case reports.
To limit the bias in disease entities frequently analyzed in
pre-malignant stages, only the 5918 clearly malignant epi-
thelial neoplasias were selected (ICD-O-3 xxxx/2 and
xxxx/3). For comparative purposes, common clinico-
pathological disease categories were generated through a
combination of diagnostic and locus codes (Table 1).
Only the 22 entities with more than 50 cases were ana-
lyzed separately, while 377 cases were not assigned to one
of these entities.
During database entry, CGH results were converted to
standard "rev ish" ISCN 1995 format. This procedure con-
tained software based syntax errors checking. The cor-
rected "rev ish" data was processed by dedicated software
[27] implemented in the Perl scripting language [34]
using complex Regular Expression based parsing algo-
rithms. Data matrices were generated, containing theBMC Cancer 2007, 7:226 http://www.biomedcentral.com/1471-2407/7/226
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imbalance status ("1" = gain, "-1" = loss, "2" = high level
gain) for each of 862 chromosomal bands (UCSC
Genome Bioinformatics [35], Golden Path mapping, May
2004 edition), or subsets thereof.
For statistical analysis, software packages available as part
of the Bioconductor [36] project for the R programming
language [37] were used. Visualization of genomic imbal-
ance profiles was performed by custom Perl routines using
the GD.pm interface [38] to the GD graphics library [39].
As a robust measure for genomic instability, the number
of chromosomes per case with one or more imbalanced
segments was determined.
Results and Discussion
In the base data set comprised of 5918 malignant cases
analyzed by CGH, breast carcinomas and precursor
lesions constituted the largest subgroup, followed by neo-
plasias of the prostate gland and stomach (Table 1). The
median aberration number per case (number of chromo-
somes with at least one abnormal segment) showed a
wide range (Figure 1), from 0 (squamous skin neoplasias,
thyroid carcinomas) to 12 (small cell lung carcinomas;
SCLC). For some of the entities at the low end of this spec-
trum, a certain bias through frequent biopsies at early
stages can be suspected (e.g. tumors of skin, thyroid, pros-
tate), although pre-maligant tumors had been excluded
from the analysis.
Imbalance hot spots in clinico-pathological entities
In the overall aberration profile, gains on chromosomal
band 8q24 represented the most common imbalance, fol-
lowed by gains involving regions on 20q, 1q, 3q, 17q,
7(q) and 5p, as well as other changes (Figure 2).
In the following overview, the most frequent regions
involved in genomic imbalances are listed, with detailed
locus and frequency information for regional hot-spots.
Since overall aberration frequencies vary greatly between
entities, no absolute cut-off values (e.g. 10% or 20%) were
used when selecting these regions. Instead, genomic
regions with clear separation from overall background in
the imbalance histograms were selected for each entity
and sorted in descending frequency of occurrence. Gains
and losses were evaluated separately.
For each entity, few outstanding observations are dis-
cussed and selected literature is provided. Histologic sub-
types are only mentioned in few entities. Because not all
involved regions can be discussed here with respect to
putative genetic targets, a selection of well characterized
oncogenes and tumor suppressor genes with involvement
in epithelial neoplasias is provided as part of Table 2.
Table 1: Distribution of 5918 malignant epithelial tumors by clinico-pathological entities, sorted by frequency of occurrence.
Diagnosis ICD-O-3 codes(1) Locus code(s) No. of cases
Breast carcinoma 81xx ... 86xx C50 667
Prostate carcinoma 814x C61 600
Gastric carcinoma 81xx ... 86xx C16 529
Ovarian carcinoma 81xx ... 86xx C56 449
Colorectal adenocarcinoma (CRC) 8140, 8480 C17, C18 430
Hepatocellular adenocarcinoma (HCC) 817x C22 371
Head-neck squamous cell carcinoma (HNSCC) 8070 C01, C09, C06, C10, C12, C13, 
C14, C30, C32
339
Thyroid carcinoma 81xx ... 87xx C73 314
Non-small cell lung carcinoma (NSCLC) 81xx ... 86xx, excl. 8041, 8045, 824x C34 254
Cervical carcinoma 81xx ... 86xx C53 226
Esophagus carcinoma (ES) 81xx ... 86xx C15 209
Renal carcinoma (RCC) 81xx ... 86xx C64 195
Nasopharynx carcinoma (NPC) 8010, 8070 C11 177
Bladder carcinoma 81xx ... 86xx C67 169
Neuroendocrine ca. and carcinoid (NE) 824x (all) 138
Melanocytic (MEL) 872x ... 877x (all) 99
Pancreas adenocarcinoma (PAC) 814x C25 88
Cholangio carcinomas 816x C221, C24 63
Small cell lung carcinoma (SCLC) 8041, 8045 C34 63
Endometrial carcinoma 81xx ... 86xx C55 56
Vulva carcinoma 81xx ... 86xx C51 53
Squamous malignancies of the skin (SQS) 807x C44 52
377 tumors from entities with <50 cases were omitted from this list. (1) ICD codes and locus codes are listed as used for automatic assignment of 
cases to the disease groups; groups do not necessarily contain cases assigned to the whole range of ICD codes.BMC Cancer 2007, 7:226 http://www.biomedcentral.com/1471-2407/7/226
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Detailed aberration profiles for each entity can be found
in the Additional file 1.
Breast carcinoma (667 cases)
Gains: 1q31 (50.8%), 8q23 (47.3%), 17q24 (31,2%),
20q (30.9%), 16p, 11q13, 19, 3q
Losses: 16q (30%), 8p23 (26.1%), 17p13 (23.5%), 11q23
(23.1%), 13q21 (22.8%)
In breast carcinomas, gains on 1q and losses on 16q con-
stitute the most frequent copy number changes of each
quality. In the literature, a cytogenetic subtype with com-
bination of these imbalances and few other genomic
changes has been associated with histology of well differ-
entiated DCIS [40] and a favorable prognosis [41]. Inter-
estingly, gains on 11q13 and 12q24 were associated with
higher metastasis-free survival in another study [42],
which also associated multiple imbalances with a bad
prognosis.
Although ERBB2 has been a known and clinically relevant
[43] amplification target on 17q, distinct amplicons map-
ping telomeric to the ERBB2 locus have been described
[44].
Prostate carcinoma (600 cases)
Gains: 8q24 (23%), 7, X
Losses: 8p21 (32.3%), 13q21 (26.5%), 6q16 (18.5%),
16q(23), 5q(21)
In contrast to other adenocarcinomas, and accounting for
the overall low copy number variations, prostate ca. usu-
ally lack the 1q gains frequent in most carcinoma entities.
While Mattfeldt et al. [45] showed a correlation of 8p loss
to higher tumor stage, the negative prognostic impact of
gains of 8q and chromosome 7 in was reported from
bioptic samples [46] and early tumors [47]. A meta anal-
ysis of published copy number data recently was provided
by Sun et al. [48].
Gastric carcinoma (529 cases)
Gains: 20q12 (36.1%), 8q23 (31.7%), 17q21 (21.2%), 7
(up to 20.8%), 13q22q31, 1q, 3q, 5p, 11q13, X
Losses: 17p13 (24.4%), 19p (18%), 18q (16.6%), 1p, 3p,
4, 5q, 9p, 12q, 16
For most chromosomes, an overall background of 4–10%
of gains as well as losses can be found. In gastric carcino-
mas as well as in some other entities, 8q gains have shown
their maximum at 8q23, proximal to the c-myc locus [49],
implying a hitherto unidentified target.
Overall imbalance pattern from all cases Figure 2
Overall imbalance pattern from all cases. For each chromosomal band (862 bands resolution) the percentage of cases with 
gains (green, upward) and losses (red, downward) is indicated.
Number of imbalanced chromosomes for different tumor  loci as indicator for overall genomic instability, in 5918 malig- nant epithelial tumors Figure 1
Number of imbalanced chromosomes for different tumor 
loci as indicator for overall genomic instability, in 5918 malig-
nant epithelial tumors. The box plots indicate the median and 
distribution of chromosomes in each tumor karyotype, with 
total or partial genomic imbalances. Only malignant cases 
(ICD-code ####/2 or ####/3) were analyzed.
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Ovarian carcinoma (449 cases)
Gains: 8q24 (43.7%), 3q26 (38.1%), 1q32 (25.3%),
12p12 (19.2%), 2, 5p, 6p, 7q, 11(q13)
Losses: 5q14 (25.2%), 4q (26.3%), 18q21 (19.8%), 17p
(19.6%), 8p (19.4%), 6q, 9q, 13q, 16q, X
Gains on 12p have been discussed as early event in ovar-
ian carcinomas with frequent occurrence in borderline
tumors [50], and several other changes have been linked
to advanced carcinomas [51]. Overall, advanced stage
tumors showed a higher grade of chromosomal instabil-
ity.
Table 2: Occurrence of most common imbalances in different epithelial neoplasias by CGH
Regional imbalance Most frequent* Above background Putative targets**
enh(1q) 
occuring in most carcinoma 
types
Breast, ovary, HCC, cervix, NPC, MEL, 
endometrial, vulva
Gastric, CRC, HCC, HNSCC, NSCLC, ES, 
RCC, bladder, PAC, SCLC, SQS
ABL2, ETV3
dim(3p) HNSCC, NSCLC, cervix, ES, RCC, NE, 
MEL (whole chr. 3), SCLC, vulva, SQS
Gastric, PAC FHIT, MLH1
enh(3q)
maxima at 3q26q27 (except 
3q25 in NPC)
Ovary, HNSCC, NSCLC, cervix, ES, 
NPC, SCLC, endometrial, vulva, SQS
Gastric, RCC, PAC BCL6, PIK3CA
dim(4q) 
frequently whole chromosome
Ovary, HCC, NSCLC, cervix, ES, bladder, 
cholangio, SCLC
Gastric, CRC, HNSCC, RCC, PAC, PRDM5
enh(5p) Thyroid, NSCLC, cervix, Gastric, ovary, CRC, HCC, HNSCC, ES, 
bladder, NE, PAC, cholangio, vulva
CDH6, TERT
dim(5q) Ovary, NSCLC, Prostate, gastric, HNSCC, ES, bladder, 
cholangio,
APC, MCC
enh(6p) HCC, MEL Ovary, NSCLC, cervix, ES, bladder, 
cholangio, SCLC, vulva
E2F3, ID4
dim(6q)
maxima at 6q16q21 or 
6q24q27
Prostate, RCC, MEL Ovary, HCC, NSCLC, cervix, bladder, NE, 
PAC, cholangio, SCLC
CCNC
enh(7) 
frequently whole 7, mostly 
max. on 7q
Prostate, thyroid, ES, RCC Gastric, ovary, CRC, HCC, HNSCC, 
bladder, MEL, PAC (7p>7q), cholangio 
(7p>7q)
7p: EGFR 7q: ABCB1, MET
dim(8p) Breast, prostate, CRC, HCC Ovary, HNSCC, NSCLC, ES, RCC, 
bladder, PAC, SCLC, vulva
DLC1, MSR1, N33
enh(8q)
ubiquitously high (exception 
NE and thyroid)
Breast, prostate, ovary, CRC, HCC, 
HNSCC, NSCLC, ES, RCC, bladder, MEL, 
PAC, cholangio, endometrial, vulva
Cervix, NPC, SCLC, SQS MYC
dim(9p)
9p or whole 9
HNSCC, bladder, PAC, SQS Gastric, NSCLC, ES, RCC, NPC, MEL, 
SCLC
ARF, CDKN2A
enh(11q13) 
frequently distinct (high-level) 
gain
HNSCC Breast, gastric, ovary, NSCLC, ES, NPC, 
bladder, MEL, PAC, cholangio
CCND1, FGF3
dim(11q23qter) NPC, NE, vulva Breast, HNSCC, cervix, ES, MEL, SCLC ATM (11q22), (LOH11CR2 
A, TSG11)
enh(12p) 
frequently whole 12; slight 
max. on 12p
NPC Ovary, CRC, HNSCC, NSCLC, ES, RCC, 
PAC, vulva
12p: CDK2, CDK4, GLI, 
KRAS 12q: MDM2
dim(13q)
mostly 13q14q21
Prostate, HCC, thyroid, bladder, NE, 
PAC, SCLC, endometrial
Breast, gastric, ovary, HNSCC, NSCLC, 
cervix, ES, RCC, NPC (max. at 13q31), 
MEL, CRC, vulva
BRCA2, RB1, STARD13
dim(16q) Breast, NPC Prostate, gastric, HCC, SCLC CDH1, ATBF1
dim(17p) Breast, gastric, CRC, cholangio, SCLC Ovary, HCC, NSCLC, cervix, ES, RCC, 
NPC, bladder, PAC, SQS
TP53
enh(17q) Breast, gastric, bladder, NE, PAC, 
cholangio, SCLC, SQS
HCC, HNSCC, NSCLC, cervix, ES, renal, 
NPC
ERBB2
dim(18q) Gastric, ovary, CRC, HNSCC, PAC, SQS HCC, NSCLC, cervix, renal, bladder, 
cholangio
DCC, SMAD4
enh(19q) NE, SCLC Breast, CRC, PAC, vulva AKT2, BAX
enh(20q) Gastric, CRC, thyroid, bladder, NE, 
PAC, cholangio
Breast, HCC, cervix, ES, renal, MEL, SCLC, 
vulva
STK15/AuroraA
Please refer to table 1 for abbreviations. * "most frequent" lists entities in which the aberration belongs to the 3 most frequent imbalances of the 
specified quality (enh = gain, dim = loss; bold if most frequent change in entity). Entities are sorted according to the total number of included cases. 
Chromosomal regions 1p, 21, 22, X and Y were omitted due to differences in reporting (e.g. exclusion of regions prone to errors in chromosomal CGH 
analysis). ** Listed are some examples of genes with oncogene (for gain regions) or tumor suppressor (for loss regions) function. However, a large 
number of possible target genes as well as structural features may exist for each region.BMC Cancer 2007, 7:226 http://www.biomedcentral.com/1471-2407/7/226
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Colorectal adenocarcinoma (430 cases)
Gains: 20q13 (53%), 13q (38.6%), 8q24 (37.2%), 7(p)
(35.6%), X(q21), 1q, 5p, 12(p), 19
Losses: 18q(22) (47.4%), 8p(22) (37.9%), 17p12 (27%),
4 (up to 23.7%), 14, 15, 22
In colorectal carcinoma, gains on 8q23q24 [52] have been
associated with lymph-node positivity. In a recent study,
gains on 20q as well as KRAS mutations could bee shown
to precede aneuploidy [53]. An overview is provided in
[54].
Hepatocellular adenocarcinoma (HCC; 371 cases)
Gains: 1q23q31 (46.6%), 8q24 (44.8%), 6p21 (22.4%),
17q (21.8%), 5, 7, 20
Losses: 4q (up to 31.3%), 8p(21) (31.3%), 13q21
(28.3%), 16q(21) (25.9%), 17p13 (25.3%), 1p, 6q, 14,
18
Losses of 8p have been shown to distinguish HCC from
other liver malignancies [55]. Also, losses on 4q and 13q
were associated with poor differentiation [56]. An over-
view of genomic changes in HCC with discussion of puta-
tive target genes is provided in [57].
Head-neck squamous cell carcinoma, excluding nasopharyngeal ca. 
(HNSCC; 339 cases)
Gains: 3q26 (59.2%), 8q24 (40.8%), 11q13 (31.9%,
many specific high-level), 5p (26.5%), Xq, 1q, 7q(21),
12p, 17
Losses: 3p (30.1%), 18q(22) (22.4%), 9p (22.4%), 11q24
(19.2%), 4, 5q, 8p, 13
Genomic imbalances in HNSCC are in line with other
squamous cell carcinomas (-3p, +3q, +5p). The high rate
of amplifications at 11p13 has been shown to involve the
cyclin D1 (CCND1) locus and to be accompanied by high
expression of the gene [58].
Thyroid carcinoma (314 cases)
Gains: 5(p), 7, 20(q)
Losses: 13q, 22, 1p
Although a number of highly aberrant cases was included
(see outliers in box plot, Figure 1), thyroid carcinomas,
including all variants, showed an overall the lowest level
of chromosomal imbalances. The subset included a large
study in post-Chernobyl tumors in children, for which
imbalances could be found only in 30% of tumors [59].
Interestingly, anaplastic carcinomas had a low median
number but high variability. Although not mapping to
regions with frequent genomic gains in the the included
cases, previous reports have shown e.g. amplification of
PRKCE on 2p21 [60] and FGF3 [61].
Non-small cell lung carcinomas (NSCLC; 314 cases)
Gains: 5p (52.8%), 3q26 (39.4%), 8q24 (35.4%), 1q(21)
(28.4%), 3, 6p, 11q13, 12p, 17q, 18p
Losses: 3p (31.9%), 4(q) (26.4%), 5q (26%), 13q21
(25.6%), 8p(21) (24%), 9 (up to 20.5%), 17p (16.5%),
1p, 6q, 10, 18q
NSCLC is a histologically heterogeneous group, consist-
ing of squamous (SCC) and non-squamous (NSCC)
cases. Imbalances have been shown to be partially shared
between the groups, with differences in the frequency of
some regional involvements [62].
Cervix carcinoma (226 cases)
Gains: 3q26qter (53.6%), 1q (up to 28.3%), 5p (27.4%),
8q24 (20.3%), 6p, 9(q), 17q, 20q, X
Losses: 2q36 (30.1%), 3p (up to 25.2%), 4 (up to 23.5%),
11q23q24 (23%), 6q, 13q, 17p, 18
The number of chromosomal changes may be influenced
by occurrence and type of HPV infection. However, in a
large study no correlation between single imbalances and
clinical parameters could be identified [63]. Losses of the
telomeric region of 2q were frequent and rarely found in
other entities.
Esophagus carcinoma (209 cases)
Gains: 3q(26) (53.2%), 8q24 (49.8%), 7p (34%), 20q13
(32.6), 1q (29.7%), 7q21 (29.7%), 5p (28.7%), Xq
(23.4%), 6p12 (22.9%), 12p (22.5%), 11q13 (22.1%),
17q21 (21.6%), 2(q), 9q
Losses: 3p (up to 37.3%), 18q (37.3%), 4 (up to 33%),
5q(21) (29.2%), 9p (26.3%), 8p (23.4%), 13q (up to
23%), 1p (22.5%), 19q (2%), 17p (20.1%), 10, 11, Xp
Esophagus carcinomas showed an overall high "back-
ground" of gains and losses, with the 2nd highest number
of imbalances per case. This group consists of cases with
squamous cell as well as adenocarcinoma or intestinal
adeno-ca. histology. Besides specific de-regulation of
oncogenes, an effect of the massive genomic changes on
chromatin structure has been discussed previously [64].
Renal carcinoma (RCC, 195 cases)
Gains: 7 (up to 33.4%), 5q(31) (32.8%), 8q23q24
(19.5%), 20 (up to 18.5%), 17q (up to 17.4%), 1qter
(13.1%), 3q, 12, 16BMC Cancer 2007, 7:226 http://www.biomedcentral.com/1471-2407/7/226
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Losses: 3p (up to 43.1%), 14q (up to 26.2%), 6q (21%),
1p (up to 20%), 9 (20%), 8p (19.5%), 13q (19.5%), 17p
(19%), 18q (18%), 2, 4, 10
Gains of 5q are a rare occurrence in other carcinomas, and
have been identified in papillary as well as non-papillary
cases [65]. An overview of accumulated karyotype data
was given in 2004 [66], proposing different cytogenetic
pathways and associating papillary RCC with a hyperdip-
loid karyotype pattern.
Nasopharynx carcinoma (NPC; 177 cases)
Gains: 12p (up to 33.9%), 1q (24.3%), 3q (22%),
8q22q23 (19.5%), 18p (17%), 11q13 (12.4%), 2(q),
4(q), 6(q), 17q
Losses: 16q (29.9%), 14q24 (27.7%), 11q23 (24.3%),
1pter (23.7%; difficult region), 9, 13q31, 17p, 19p
In contrast to some other carcinoma entities, the maxi-
mum of gains mapped clearly proximal to the c-myc
region. A meta-analysis of CGH data in NPC was recently
provided by Li et al. [67]. In concordance with the low
number of NPC cases with 8p deletion, the oncogeneti-
cally relevant DLC1 on 8p22 has been reported to be inac-
tivated by methylation rather than copy number change
[68].
Bladder carcinoma (169 cases)
Gains: 20q (21.3%), 8q (20.7%), 17q (20.7%), 11q13
(19.5%), 1q21 (17.8%), 5p, 6p, 7, 10p
Losses: 9 (26%), 13q21 (17.8%), 4q (up to 14.2%), 11p
(14.2%), 5q (14.6%), 2q32, 8p, 6q, 18q, X, 17p
While some of the imbalances (e.g. 8q, 17q and 20q gain,
11q13 gain/amplification) were frequent in other entities,
losses on chromosome 9 were exceptionally high in tran-
sitional cell carcinoma (115 cases). In contrast to other
squamous cell carcinomas, gains on 3q were rare (3 of 40
bladder SCC). In one study included in the data, some dif-
ferences between histological and etiological subtypes of
bladder carcinomas were presented [69].
Neuroendocrine carcinoma and carcinoid (138 cases)
Gains: 19 (26.1%), 20 (up to 18.1%), 17q (up to 17.4%),
5p (15.9%)
Losses: 11q22q25 (20.3%), 13q21 (18.1%), 3p (up to
15.5%), 6q22 (13%), 10q25q26 (13%)
Possibly due to the heterogeneity of this group, a diffuse
background of whole chromosome gains was observed.
The genetics of neuroendocrine tumors was recently
reviewed with consideration for inherited syndromes as
well as molecular cytogenetic results [70].
Malignant melanocytic neoplasias (99 cases)
Gains: 8q(21) (36.3%), 6p (32.3%), 1q (22%), 7, 20q,
11q13
Losses: 6q(24) (29.3%), 10 (q22) (22.2%), 3 (up to
21.2%), 9p (21.2%), 13q, 1p, 11q23q24
In contrast to most epithelial malignancies, gains on 6p
can be found in a large proportion of malignant melano-
mas. Above background losses on 10q are found in few
other entities, too. Similar to other entities gains on 8q,
1q, 20q and chromosome 7 can be observed. A compre-
hensive overview about molecular-cytogenetic techniques
in the analysis of melanocytic lesions was given by Bauer
and Bastian [71].
Pancreas adenocarinoma (88 cases)
Gains: 20q (up to 30.7%), 8q(23) (26.2%), 17q (up to
21.6%), 12p11 (19.3%), 7p (18.2%), 3q (up to 17.1%),
5p, 11(q13), 14, 15qter, 16, 19q
Losses: 18q (35.2%), 9p(23) (29.6%), 13q (18.2%), 3p
(up to 17.1%), 6q(21) (17.1%), 8p (17.1%), 17p13
(15.9%), 4, 15q, 10q, 12q
This subset only includes pancreas adenoocarcinomas,
omitting endocrine tumors.
High level copy number amplifications have been shown
e.g. for ERBB2 (17q12) and EGFR (7p12). Interestingly,
the maximum for gains on 8q (8q22) is proximal to the c-
myc region. This fact was also mentioned in a recent over-
view of genomic screening results in pancreas ca. [72].
Cholangio-carcinomas (intra- and extrahepatic; 63 cases)
Gains: 8q22 (42.9%), 17q (up to 39.7%), 20q (34.9%),
11q13 (23.8%), 15q (up to 23.8%), 3q(26) (20.7%), 7p
(up to 20.7%), 13q (up to 20.7%), 5p (up to 19.1%), 1q,
6p, 12q23q24
Losses: 1p34p36 (up to 22.2%), 4q (up to 20.6%), 17p
(19.1%), 5q(14), 6q, 13q, 18qter, X
Gains on 15q were reported in up to 36% (in a study of
Korean intrahepatic cholangio-ca. [73]), but rarely seen in
other entities.
Small-cell lung carcinoma (SCLC; 63 cases)
Gains: 19 (up to 44.4%), 3q (up to 41.3%), 17q23
(41.3%), 1p31p34 (38.2%), 8q(23) (36.5%), 20q (up to
30.2%), 14q31q32 (26%), 1q (up to 25.4%), 9q31q34,
6p, 13q32BMC Cancer 2007, 7:226 http://www.biomedcentral.com/1471-2407/7/226
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Losses: 3p (84.1%), 4 (up to 74.1% on 4qter), 13q(14)
(69.8%), 10(q) (41.3%), 17p13 (33.3%), 2(q23q24)
(31.8%), 8p (25.4%), 9, 11, 15, 6q, 16q
SCLC had the highest number of chromosomal imbal-
ances (median 12 involved chromosomes per case). Also,
some of the imbalances constituted the overall highest
fractional aberrations in all datasets (e.g. >80% losses on
3p), as well as very frequent losses on 4q, 13q and 10q.
Although frequent gains on 7p had been reported from
array CGH of SCLC cell lines [74], this region was rarely
involved in the mostly clinical specimen analyzed by
chromosomal CGH.
Endometrial carcinoma (56 cases)
Gains: 1q (50%), 8q(22) (39.3%), 3q26 (14.3%), 10 (up
to 14.3%)
Losses: 10q (12.5%), 13q (10.7%), 14q, 9q
As in e.g. nasopharynx ca., SCLC and pancreas ca., the
maximum of 8q gains was proximal of 8q24. Endometrial
ca. show an exceptional high rate of gains on 1q, which
were also the most frequent change in a series of 98 cases
not available for inclusion here [75]. Interestingly, chro-
mosome 10 was also frequently involved (both gains and
losses).
Carcinomas of the vulva (53 cases)
Gains: 3q (45.7%), 8q(23) (34%), 1 (up to 28.3%),
5p(15) (26.4%), 20q (24.5%), 9q (20.8%), 6, 7, 12, 14,
19, X
Losses: 3p (22.6%), 4p (22.6%), 11q23q25 (20.8%),
13q14 (13.2%), 8p, 10, X
Vulvar carcinomas showed an imbalance pattern charac-
teristic for squamous cell neoplasias, with a high rate of
gains on 8q23 and especially 3q. As in cervix ca., the most
frequent changes could not be related to HPV status [76].
Squamous cell carcinomas of the skin (52 cases)
Gains: 3q (11.5%), 17q (11.5%), Xq (9.6%), 1q, 8q, 14q
Lossses: 9p21 (19.2%), 3p (13.5%), 18q (13.5%), 17p
(9.6%)
While containing many cases of borderline malignant
behaviour, squamous skin neoplasias had the overall low-
est aberration frequencies (median 0). This group did not
include the pre-malignant keratoacanthomas, for which a
frequent gain of 11q and cyclin D1 overexpression had
been shown [77].
Disease-specific Involvement of most frequently aberrant 
chromosomes and relationship of overall aberration 
profiles
Several chromosomal hot spot regions showed a pro-
nounced disease related variation. The most prominent
regions scoring high in specific entities are listed in Table
2. To reduce sampling bias (e.g. entity specific inclusion of
a high proportion of early stage cases) top-scoring aberra-
tions were defined as the most frequent gains or losses in
each entity. Some additional imbalances which occured
only in few entities at high levels are listed in Table 3. In
an attempt to identify the relation of single case aberra-
tion profiles, a cluster analysis of all 5043 informative
cases was performed. For that purpose, a band specific
matrix with 86 bands resolution was generated, of which
the 55 intervals most frequently involved in imbalances
were selected (top-scorers in one or more entities, ref.
Tables 2 and 3; e.g. "8q2"). Hierarchical cluster analysis
revealed the complexity of the case-specific aberration
patterns, and was able to visualize concordance of imbal-
ance patterns and disease categories in small groups of
cases (Figure 3).
To reduce the complexity of the data and simplify the
detection of similarities in the aberration patterns of dif-
ferent entities, region specific aberration frequencies of all
entities were clustered. For each of the 55 selected inter-
vals, the sum of gains – losses was calculated, resulting in
a 22 × 55 matrix (entities × intervals). During hierarchical
cluster analysis, values were normalized over each entity's
intervals, to account for differences in genomic complex-
ity. Figure 4 depicts the result of the cluster analysis, in
which overall similarities and differences in the different
entities become apparent.
Differences in aberration profiles in some instances will
reflect the general histological type, which is substantiated
by the close relation of overall profiles e.g. from clinico-
pathological groups containing squamous cell carcinoma
cases (group NSCLC/esophagus/HNSCC/cervical/vulva in
Figure 4). To evaluate this effect, the most frequent his-
topathological entities (adenoca., squamous cell ca.,
hepatocellular ca., ductal breast ca., transitional cell ca.,
intestinal adenoca.) were selected. Additionally, adeno-
carcinomas of the prostate were put in a separate group,
due to the previous observation of specificities in the
imbalance profile (e.g. overall lack of 1q gains). Cluster-
ing was performed analogous to the method described
above. Figure 5 visualizes the clustering of those his-
topathological entities.
In comparing the most frequent imbalances for their
occurrence in different entities, some general observations
stood out. Gains involving the terminal part of 8q were
ubiquitously found, and often belonged to the most fre-BMC Cancer 2007, 7:226 http://www.biomedcentral.com/1471-2407/7/226
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quent imbalances in the respective entities. Hovever, they
were rarely detected in neuroendocrine carcinomas and
thyroid neoplasias. Interestingly, in some entities the
maximum of detected abnormalities mapped proximal of
8q24 (e.g. 8q21 in melanocytic NPL and 8q22 in NPC
and cholangio ca.). How much this reflects a true differ-
ence in regional involvement, and therefore may point to
differential target gene involvement has to be left open
here.
Gains on 1q with maxima on 1q2 were also frequent, and
were the most frequent changes in breast, hepatocellular
and endometrial carcinomas. However, 1q gains were
comparatively infrequent in carcinomas of the prostate
and bile ducts as well as in renal and colorectal ca. Overall
gains on 3q26q27 combined with losses on 3p were char-
acteristic for squamous cell carcinomas and SCLC, with
3q gains also being frequent in ovarial ca. and other enti-
ties.
Clustering of 5043 malignant epithelial neoplasias by the pattern of gains and losses, using regions previously defined as highly  aberrant in one or several entities (ref. tables 2 + 3) Figure 3
Clustering of 5043 malignant epithelial neoplasias by the pattern of gains and losses, using regions previously defined as highly 
aberrant in one or several entities (ref. tables 2 + 3). For each case (x-axis), gains (green) and losses (red) are indicated for the 
corresponding chromosomal regions (55 selected bands; y-axis). The color bar codes on top indicate the cases' assignments to 
the different clinico-pathological entities and histological groups (color code is provided in the additional file 1).
Table 3: Selected imbalances with high penetrance limited to one or few entities
Imbalance Occurrence Comment
dim(2q22q31) SCLC (up to 31.8%) Profile appears region-specific; however, SCLC cases have very rich imbalance 
pattern with more frequent changes
dim(2q33q37) Cervix (up to 30.1%) Specific terminal 2q deletions are else only found in low frequency in NSCLC and 
bladder lesions
enh(5q21q35) RCC (up to 32.8%) Specific regional 5q gains are near exclusive for renal carcinomas, and are here 
part of whole chromosomal changes (20%) or limited to the region
dim(10q) SCLC (up to 41.3%), melanocytic, 
endometrial
Rare as specific changes above "background"
enh(13q) CRC (up to 38.6%), gastric 13q gains are rare except in CRC, esp. compared to the frequent losses in the 
regionBMC Cancer 2007, 7:226 http://www.biomedcentral.com/1471-2407/7/226
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While 5p gains were found in various entities, gains on 5q
were frequent only in ca. of thyroid and kidney, as were
gains on chromosome 12. Overall, 13q losses could be
detected in most entities. In contrast, 13q gains were pre-
dominant in cholangio ca. and also frequent in colorectal
and gastric carcinomas.
Region specific gains involving 11q13 were found in a
number of entities (bladder ca., HNSCC, pancreas, pros-
tate, skin, ovary, gastric, NSCLC). Interestingly, of the
overall 692 cases with gain on 11q13, 18% had a loss of
the telomer of 11q by CGH (Figure 6). Since a strong
selective pressure for such a switch in aberration quality in
linked regions can be suspected, this observation may
point towards targeting of both genes with oncogene and
tumor suppressor functions on 11q in these tumors.
When comparing overall aberration patterns, entities con-
taining squamous cell carcinoma cases (HNSCC, NSCLC,
cervix and vulva ca., esophagus ca.) appeared related, with
a common pattern offrequent losses on 3p, gains on 3q,
8q and varying gains on 1q and 5p. NPC showed a slightly
diverging pattern, with predominant 12p gains and 14q
losses in addition to slightly lower levels of those imbal-
ances.
Interestingly, in both unselected renal carcinomas as thy-
roid neoplasias, the average imbalance profiles included
frequent gains on chromosomes 5, 7 and 12, while lack-
ing the dominance of gains 1q and 8q found in most
other entities.
Apart from these observations, one should refer to the
accompanying figures for a general comparison of pat-
terns in different clinico-pathological groups. Also, the
use of the Progenetix website tools is encouraged.
Conclusion
This study attempted an overview of chromosomal imbal-
ance profiles in epithelial neoplasias, based on a large col-
Clustering of carcinoma entities by their overall imbalance pattern Figure 4
Clustering of carcinoma entities by their overall imbalance pattern. For each of the selected chromosomal regions, aberrations 
were summarized (percent gain – percent loss). After normalization of all regions over the respective entity, the color intensi-
ties represent the relative contribution of regional gains and losses to the overall aberration patterns.BMC Cancer 2007, 7:226 http://www.biomedcentral.com/1471-2407/7/226
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lection of case-specific chromosomal imbalance data
from published chromosomal CGH experiments. The
most striking observations were the high frequency of a
limited set of changes (+1q, +3q, +7, +8q, -13q, -17p, -
18q, +20q ...), of which different subsets occurred in most
entities. The iterative involvement of certain genomic
regions in either gains or losses is a strong argument for
the non-random incorporation of these changes into the
tumor cell genomes, with common as well as disease spe-
cific changes becoming apparent. One may speculate that
the recurring combination of a limited set of imbalance
hot-spots is concordant with the multistep process of can-
cer development [78], and that these regions point
towards preferential oncogenetic targets. For a detailed
discussion of the region-specific changes and patterns
related to single disease entities, only examples could be
given in the context of this article. The existing literature
should be considered for additional information.
This descriptive analysis of local genomic imbalance fre-
quencies cannot be able to address some important ques-
tions, e.g. regarding the biological significance of the
observed changes. Although certain genomic copy
number amplifications and segmental deletions have
been shown to involve oncogenetically relevant genes in
various malignancies (see Table 2 and for reference e.g.
[79-82]), some of the recurring genomic imbalances
might be as well pure epi-phenomena of defects in the
molecular maintenance of the genome. In respect to the
limited spatial resolution and phenomenological nature
of the data, the discussion and validation of specific target
genes should be left to meticulously crafted molecular-
biological experiments.
Cluster analysis of case specific chromosomal CGH data
has been used previously to identify subsets of cases in
single clinico-pathological entities [45,83,84]. Current
methodology appears more suited for limited data sets,
while new algorithms have to be developed for automatic
Clustering of different histologies in carcinomas by their overall imbalance pattern Figure 5
Clustering of different histologies in carcinomas by their overall imbalance pattern. Here, the most frequent histological types 
were automatically grouped for their overall imbalance profiles. Since considerable differences had been found for adenocarci-
noma cases from the prostate (most notably lack of 1q gains), this group was separeted from the overall adenocarcinoma 
group.BMC Cancer 2007, 7:226 http://www.biomedcentral.com/1471-2407/7/226
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subgroup detection from large, heterogeneous series of
CGH data [85,86]. This is especially challenging regarding
the variant background of chromosomal copy number
changes found in certain tumor types, which may be
based on aberrant expression of regulatory genes [41].
Since genomic copy number changes constitute only one
of many mechanisms leading to aberrant gene regulation,
the deduction of oncogenetic pathways from CGH data
will remain a challenging project. However, the combina-
tion of existing large-scale data collections and current
high resolution screening techniques should provide
additional pieces for these puzzles. For that purpose, the
Progenetix data collection is open for inclusion into data
mining projects.
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